News
Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
Hims & Hers ( HIMS 19.03%) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth ...
Hims & Hers reports 111% YoY sales growth & 70%+ gross margin. Discover their growth potential, risks, & why it's a Buy recommendation.
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
21h
MarketBeat on MSNHims & Hers Stock Rises on Fundamentals and Squeeze PotentialThere are only a few companies that come around every half-decade or so that really get the gears turning in terms of having ...
Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results